Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Failed trial puts Shield shares on the rollercoaster

This article was originally published in Clinica

Executive Summary

Shield Diagnostics' test for the blood clotting protein, activated factor XII (AFT), is a better predictor of heart disease than measurements of lipid levels or fibrinogen, according to preliminary data from the multicentre Northwick Park study. However, the company has been rocked by news that AFT data from the much larger US ARIC study of cardiovascular is useless. Shield's shares had climbed to an all time high of 790 pence earlier this month but tumbled back to around 620 pence on news that blood samples stored for use in the 16,000-patient ARIC study had clotted during storage, rendering them useless. Shares closed up at 690 pence on news of the Northwick Park data on March 23rd.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT084074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel